| Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150] | Technology appraisal guidance | TBC |
| Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284] | Technology appraisal guidance | |
| Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738] | Technology appraisal guidance | TBC |
| Seladelpar for previously treated primary biliary cholangitis ID6429 | Technology appraisal guidance | |
| Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273] | Technology appraisal guidance | TBC |
| Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183] | Technology appraisal guidance | TBC |
| Semaglutide for managing overweight and obesity and the reduction of associated cardiovascular risk (ID6441 including a review of TA875 and TA910) | Technology appraisal guidance | TBC |